Establishing a Robust Transcatheter PDA Closure Program for Extremely Low Birth Weight Infants

By Shyam Sathanandam, MD; Leah Apalodimas, MSN, APN, CCRN, CPNP; Mark Weems, MD; B. Rush Waller, MD; Ranjit Philip, MD

Introduction

Extremely Low Birth Weight (ELBW) infants (weight <1kg at birth) frequently present with a large, hemodynamically significant Patent Ductus Arteriosus (PDA).1 The PDA in ELBW infants can contribute to worse outcomes.2-4 However, there are no management algorithms that exist for ELBW infants with a hemodynamically significant PDA. Established treatment options include the administration of cyclooxygenase (COX) inhibitors and surgical ligation of the PDA (SLP) via a thoracotomy. COX-inhibitors are not always effective.5-7 SLP has not been shown to positively impact long-term sequelae.8-9 Procedural complications and long-term sequelae have made this option less attractive. There is also a general belief that treatment of the PDA beyond the first few weeks of life in the ELBW infants may not significantly alter outcomes.1,3,5,6 This has led to a practice of a trial of medical therapy in the first 2-3 weeks of life, and if unsuccessful, no further intervention is sought.2,5-7 Many neonates continue to languish with a large, hemodynamically significant PDA on a ventilator with evolving Chronic Lung Disease (CLD) and Pulmonary Hypertension (PHT).

Transcatheter PDA closure (TCPC) is the established mode of treatment for PDAs in children >5 kg.10 TCPC in ELBW infants is slowly being implemented by many centers.11-13 Advantages of TCPC in ELBW newborns include immediate PDA closure compared to several days to weeks until closure with medications,11-12 and that TCPC is less invasive than SLP.11-12 Despite these perceived advantages, TCPC does not feature in the current treatment algorithm for PDA in the ELBW newborn. The challenges that prevent this therapy from becoming readily available to this population of patients include: a general concern for any procedural adverse events in extremely small babies, need for miniaturizing catheters and devices required for TCPC, concern of transporting the patient to a different environment for the procedure, use of radiation and contrast to perform TCPC, and lack of awareness of the availability of TCPC as a treatment option for ELBW newborns, among others. The aim of this report is to describe how we established a robust TCPC program for ELBW infants.

The TCPC Program for ELBW Infant

Currently, we have a one-of-a-kind infants comprehensive PDA program unlike anything in the United States which has enabled us to provide exceptional care for these infants both during their hospitalization and throughout their childhood. This has been accomplished through several years of extremely collegial and collaborative work between the neonatologists, cardiologists, congenital cardiac surgeons, and pulmonologists, among others, along with support from hospital administration. Generally, any ELBW newborn with a large, hemodynamically-significant PDA would have a course of medical therapy to close the PDA. If the therapy fails (the PDA is still large and hemodynamically significant based on echocardiographic and clinical assessment),
SAVE THE DATE
PICS-AICS
MGM GRAND LAS VEGAS
SEPT. 5-8, 2018
WWW.PICSYMPOSIUM.COM

NEW!
AT PICS-AICS
3D IMAGING
WED. SEPT. 5, 2018
WWW.PICSYMPOSIUM.COM
hospital discharge. Recently, we have started an out-patient PDA clinic for follow-up of these patients. The PDA clinic encompasses a multi-specialty team that is invested in discovering the long-term outcomes of ELBW infants who continue to have PDAs and those who have undergone PDA closures. Cardiology, pulmonology, developmental pediatrics, nutrition, and nursing are all integral members of this multi-specialty team. Infants that are seen by pulmonology for bronchopulmonary dysplasia and also have a PDA (open or closed) are seen in this clinic by both pulmonology and cardiology teams with expertise in pulmonary hypertension. Growth and development are vital areas of tracking, most especially in our formerly, ELBW, premature patients. Nutrition and feeding abilities are regularly assessed at these visits as well.

**TCPC Technique**

All cases are performed in the cardiac catheterization lab (Figure 1). The interventional cardiologist rounds with the NICU staff for at least two days prior to the procedure in order to understand how to best manage the patient during the procedure. Our specialized technique included making modifications to how we transport the patient and how the staff cares for them in the catheterization laboratory. Prior to transport, the entire team including the cath lab staff, the interventional cardiologist, and anesthesia team receive bedside hand-off in the NICU.

We utilize a Giraffe Shuttle which is a mobile isolate that provides electrical power for ventilator support and thermoregulation. Intubated patients remain ventilated with the Neopuff (versus manual bag ventilation) in order to decrease risk of extubation, maintain lung volumes, and decrease risk of causing oxygenation-ventilation problems in these fragile infants. Our patients are returned to the NICU post-procedure in the same fashion with another bedside hand-off with the NICU team. In the catheterization lab, the temperature is increased to 75 degrees Fahrenheit and a heat lamp is placed over the patient to support thermoregulation. A temperature probe is placed in the esophagus to monitor core temperature throughout the procedure. The patient is kept warm using heat lamps and a heating blanket with continuous temperature monitoring via an esophageal probe. The blood pressure (BP) cuff is placed around the left lower extremity and is cycled every 5-minutes. A Trans-Thoracic Echo (TTE) is performed initially by the non-invasive cardiologist standing at the head end of the table to determine ideal windows for scanning during the procedure. Measurement of the PDA length, and diameters at the Pulmonary Artery (PA) end, and aortic end are obtained from various windows. The patient is prepped and draped in the standard sterile fashion. The patient is draped with a clear drape so that the entire body can be visualized at all times during the procedure. A 4-French, 7cm, introducer sheath is placed in the right femoral vein using ultrasound-visualized at all times during the procedure. A temperature probe is placed in the esophagus to monitor core temperature throughout the procedure. The patient is kept warm using heat lamps and a heating blanket with continuous temperature monitoring via an esophageal probe. The blood pressure (BP) cuff is placed around the left lower extremity and is cycled every 5-minutes. A Trans-Thoracic Echo (TTE) is performed initially by the non-invasive cardiologist standing at the head end of the table to determine ideal windows for scanning during the procedure. Measurement of the PDA length, and diameters at the Pulmonary Artery (PA) end, and aortic end are obtained from various windows. The patient is prepped and draped in the standard sterile fashion. The patient is draped with a clear drape so that the entire body can be visualized at all times during the procedure. A 4-French, 7cm, introducer sheath is placed in the right femoral vein using ultrasound-visualized at all times during the procedure. Intravenous heparin bolus is not administered. Procedural heparinized saline flushes are sufficient to maintain the activated clotting times between 200-250 seconds. Prophylactic antibiotic is administered.

Under fluoroscopy, a 4-French Glide catheter (Terumo, Japan) and a 0.035”, Wholey wire (Medtronic, Minneapolis, MN) are used to access the PDA antegrade and to cross into the aorta. Hand injection of contrast through this catheter is used to obtain an aortogram in straight lateral projection for measurement of the PDA (Figure 2). An appropriate size Microvascular plug (MVP; Medtronic, Minneapolis, MN) is advanced through the same catheter and deployed in position across the PDA (Figure 2). If an Amplatzer device (Abbott Structural Heart, Abbott Park, IL) is chosen for occlusion, the femoral venous sheath is exchanged for a longer delivery sheath/catheter over a wire placed in the descending aorta through the PDA. The device is delivered through this sheath using standard technique. Presence of residual shunting and obstruction to the aorta or the left pulmonary artery (LPA) by the device are checked using TTE with the device repositioned as necessary (Figure 2). The esophageal temperature probe on fluoroscopy usually corresponds to the aortic end of the PDA and is helpful in device positioning.
A hand injection of contrast is performed through a Y-adapter connected to the end of the catheter in a straight lateral projection to assess device positioning and stenosis of the proximal LPA (Figure 2). TTE, in conjunction with palpation of the femoral arterial pulsations and non-invasive BP measurement in the left lower extremity prior to and post-device occlusion, helps rule out stenosis of the descending aorta. Once the position of the device is found to be acceptable, it is detached from the delivery wire, the catheter and sheath are removed, and patient is transported back to the NICU. Follow-up TTE and chest radiographs are obtained 6-hours post-procedure and as clinically indicated thereafter. An earlier practice of obtaining a lower extremity venous and arterial Doppler following the procedure is not followed anymore as there have been no access vessel complications.

Lessons Learned

As with any procedure, TCPC in ELBW infants has a learning curve. We have achieved a level of comfort that the median procedure time (physician scrub in to scrub out time) is less than 30 minutes; the fluoroscopy time is less than 5 minutes (median radiation exposure < 4 mGy), the median contrast volume used is <2mL/kg among the most recent 50 ELBW patients referred for TCPC. Figure 3 illustrates the gradual decline in the procedure age and weight of the patients in whom TCPC was performed. More recently, with referrals coming from other centers, we have seen a slight increase in the procedure weight of the ELBW infants undergoing TCPC. Similarly, there is a gradual decline in the procedure time and fluoroscopy time with experience.

The learning curve started nearly 6 years ago, when we noticed that formerly premature infants who were now much older were being referred for pulmonary hypertension studies to the catheterization laboratory. These older infants had severe bronchopulmonary dysplasia, sometimes with ventilator dependency, and large PDAs with some already developing irreversible pulmonary hypertension. Most of these children had undergone medical therapy to attempt PDA closure earlier in life. We began to wonder, if there was an intention to close the PDA with medical therapy that failed, then why were they not referred sooner for another form of PDA closure? We, therefore, decided to embark on altering the traditional TCPC technique to be suitable for ELBW infants.

The first step was to understand the morphology of the PDA in ELBW infants. What we discovered was that the morphology of these PDAs resemble their fetal counterpart and are large and long with a slightly tortuous connection to the PA giving a “hockey stick” appearance (Figure 4). We defined this morphology as Type F PDAs, as they are “fetal type” PDAs and do not fit the conventional classification system proposed by Krichenko.

Having an understanding of the distinctive morphology of the PDAs in premature infants was an important step in the process of...
Our goal is to perform TCPC limiting the occurrence of any adverse event. Every catheter maneuver that is made within the patient must be intentional and precise with care taken to not impose any superfluous movements. Precision of movements will help decrease procedure time and prevent complications. We prefer the use of an angled glide catheter, which is one of the most flexible catheters, along with the 0.035” Wholey wire with an atraumatic tip. This combination prevents catheter-wire size mismatch and is less likely to cause any vessel injury. Initially, like many other operators, we used the Amplatzer Vascular Plug–II (AVP-II) device for TCPC. However, there are several pitfalls when using this device. As stated earlier, the PDA size is very consistent at least in the smaller (<1.5 kg) neonates. In our series, the median PDA diameter at the PA end was 3.4 mm, and the median length of the PDA was 10.6 mm (Figure 4). It was frustrating that the 4mm AVP-II was a bit too small for the PDA, and the 6mm AVP-II was a bit too large, and a 5mm AVP-II was not manufactured. Therefore, the MVP-5Q device is practically a one-size-fits-all for PDAs for patients <1.5 kg. This was the most commonly used device in our series with its use in 58 of the 80 children <2 kg that underwent TCPC. Secondly, the disks of the AVP-II have the potential to cause stenosis of either the LPA or the aorta. We had one LPA stenosis caused by the use of a 6 mm AVP-II in a 1 kg neonate. This complication was identified during the procedure itself and the device was retrieved easily. The PDA in that particular patient went into spasm and did not reopen leading to a “deviceless” closure of the PDA. The MVP device being a “diskless” device is less likely to cause vessel stenosis. Third, extremely small patients do not tolerate stiff wires and delivery cables to cross the tricuspid and pulmonary valves that are required for device deployment. The delivery cable of the MVP is less stiff compared to other devices and, consequentially, easier to maneuver through the heart in neonates weighing as small as 600 grams. In the past two years, we have almost exclusively used the MVP, especially in neonates <1.2 kg because of the less stiff delivery cable. The MVP has the advantage of being delivered through the same catheter that is used to cross the PDA, avoiding the need for a sheath exchange unlike the AVP-II.

We had one mortality relatively early in our experience during the sheath exchange needed to implant an AVP-II in an 840-grams neonate. The sheath exchange led to an inadvertent laceration of the inferior vena cava that was recognized only at the end of the procedure, and the infant could not be resuscitated. Besides this one mortality and the LPA stenosis that was immediately “cured” by removing the device, there was one other procedure-related complication. The third complication was in a 900-grams child that had a small pericardial effusion before the procedure that increased in size 24-hours post-procedure. Though there were no signs of tamponade in this patient, it was decided to electively drain the effusion percutaneously. The effusion was hemorrhagic in nature and therefore attributed as a procedural complication. In fact, all three adverse events happened relatively early in our experience when the AVP-II was exclusively utilized. There have been no TCPC procedure-related adverse events in the most recent 60 patients and none with the use of the MVP. We, therefore, believe that if TCPC is performed carefully, it is a safe procedure for most ELBW infants and the MVP may be the most appropriate device to use in the smallest of patients. With the AD0-II AS US IDE trial (Amplatzer Duct Occluder II Additional Sizes, United States Investigation Device Exemption Clinical Trial, IDE#G160190, Identifier NCT03055858 on clinicaltrials.gov) recently completing patient enrollments, we could soon have an FDA-approved device available for TCPC in ELBW infants.

As we progressed to performing TCPC earlier in life, we found a distinct benefit in early TCPC vs. delayed TCPC. Early TCPC (within the first 4 weeks of life) seems to afford faster weaning off ventilator and oxygen support and lower incidence in development of Pulmonary Hypertension (PHT). In fact, ELBW neonates undergoing TCPC early in life seem to have no PHT compared to their older counterparts, who almost invariably seem to have PHT associated with their large PDA. It becomes challenging to treat the PHT in these patients with pulmonary vasodilators in the presence of large left-to-right shunt across the PDA. We have not encountered the dreaded “Post-PDA Ligation Syndrome” that sometimes occurs after surgical PDA ligation. Anecdotally, when we have performed TCPC early, we have observed that these patients have not gone on to develop IVH or NEC post-TCPC. It is hard to prove

Figure 5. Graph showing the increase in the number of patients referred and the number of referring centers for TCPC for ELBW infants over the past 3 years. Each color bar represents a different center.

Figure 6. Graph showing the increase in the number of ELBW infants undergoing TCPC along with a decline in the number of surgical PDA ligations from 2014-2017.
if PDA closure early in life prevents the development of IVH and NEC. A randomized control trial comparing outcomes following early TCPC for large, hemodynamically-significant PDA vs. no PDA closure may be necessary to answer the question of whether early TCPC is beneficial with improved patient outcomes. In our fairly large experience with TCPC in ELBW infants, there seems to be a trend towards possible benefit to closing the PDA earlier in life.

Expansion of the TCPC Program

This experience has sincerely convinced us that TCPC is the “correct” treatment for ELBW infants with a large, hemodynamically significant PDA. This conviction has genuinely made us resolve that TCPC should be in the management algorithm for ELBW infants with a large PDA. We are absolutely dedicated to the care and welfare of these ELBW infants, and are determined to expand the availability of this procedure to all at-risk ELBW infants. Our series of 80 TCPC in children <2 kg, with 37 being performed in children <1 kg to date, represents the largest series in ELBW infants. The neonate that underwent TCPC at 640 grams is the smallest patient on record to undergo this procedure. This has led to a spike in the referrals for this procedure. Figure 5 demonstrates the increasing number of centers referring ELBW infants for TCPC and Figure 6 demonstrates the change in practice at our site from SLP to TCPC for failure of pharmacotherapy. Our greatest success is reflected by the increasing referrals from our neonatology colleagues in the smaller outlying communities of rural Arkansas, Mississippi, and Tennessee after receiving informative brochures detailing our experience. As we continue to successfully perform this procedure on infants <1 kg, we anticipate that the number of TCPCs performed at our site will increase exponentially. We even had one patient referred for TCPC from a center that is 6 hours away from us. This 700-gram neonate was transferred to our facility and back after the procedure via air transportation. This patient has subsequently been discharged home and is without any major sequela. This is a huge accomplishment and represents the true success of our program.

Conclusions

In summary, TCPC is feasible and is safe in most ELBW infants. TCPC is less invasive than surgical PDA ligation and will definitively close the PDA, unlike medical therapy. The MVP and the ADO-II AS may be the devices ideally suited for these patients. We established a robust TCPC program which is all inclusive from management of ELBW newborns that failed medical therapy to close the PDA to long-term follow-up in a dedicated, multi-specialty PDA clinic. The success of the program at our center should be easy to replicate throughout the country. With the increasing use of this procedure, TCPC is likely to find its way into the management algorithm of ELBW infants with a large, hemodynamically-significant PDA.

If you want to learn more about TCPC in ELBW infants, you can consider attending the 2018 International PDA Symposium. This inaugural symposium will be held on May 18th-19th, 2018 at The Westin in downtown Memphis, Tennessee. This is an exciting and creative approach to foster multi-specialty dialogue among neonatologists, pediatric cardiologists, and pediatric cardiovascular surgeons, as well as other sub-specialists. The symposium will feature informative talks, debates, hands-on sessions, and a live TCPC case. Experts from around the world in each of these specialties will be in Memphis to promote lively discourse. A panel discussion at the end of the meeting will attempt to come up with a consensus statement.

References

5. Koehne PS, Bein G, Alexi-Meskhishvili V, Weng Y, Bühler C, Obladen M. Patent ductus arteriosus in very low birthweight...


**Corresponding Author**

Shyam K. Sathanandam, MD, FSCAI
Medical Director of the Invasive Cardiac Imaging and Interventional Catheterization Laboratory
LeBonheur Children Hospital
University of Tennessee Health Science Center
Memphis, TN USA
Tel: 901.287.6380; Fax: 901.287.5915
shyam78@gmail.com
The only transcatheter pulmonary valve specifically designed for RVOT conduits and bioprosthetic valves. The longest studied, with the largest body of clinical evidence at 7 years post-implant. Over 11 years of implants, more than 12,000 patients’ lives have been changed. Melody TPV — The Right Choice for Your Patients

Melody Transcatheter Pulmonary Valve, Ensemble II Transcatheter Valve Delivery System

Important Labeling Information for the United States

Indications: The Melody TPV is indicated for use in the management of pediatric and adult patients who have a clinical indication for intervention on a dysfunctional right ventricular outflow tract (RVOT) conduit or surgical bioprosthetic pulmonary valve that has a moderate regulation, and/or a mean RVOT gradient ≥35 mm Hg.

Contraindications: None known.

Warnings/Precautions/Side Effects:
- DO NOT implant in the aortic or mitral position. Pre-catheter bench testing of the Melody valve suggests that valve function and durability will be extremely limited when used in these locations.
- DO NOT use if patient’s anatomy precludes introduction of the valve. If the patient’s anatomy does not allow for a successful deployment, the valve should be removed.
- DO NOT use if there are clinical or biological signs of infection including active endocarditis. Standard medical and surgical care should be strongly considered in these circumstances.
- Assessment of the coronary artery anatomy for the risk of coronary artery compression should be performed in all patients prior to deployment of the TPV.
- Minimize the risk of conduit rupture, do not use a balloon with a diameter greater than 110% of the nominal diameter (original implant size) of the device; care should be taken to pre-dilate the intended site of deployment, or for deployment of the TPV.
- The potential for stent fracture should be considered in all patients who undergo TPV placement. Radiographic assessment of the stent with chest radiography or fluoroscopy should be included in the routine postoperative evaluation of patients who receive TPV.
- If a stent fracture is detected, continued monitoring of the stent should be performed in conjunction with clinically appropriate hemodynamic assessment. In patients with stent fracture and significant associated RVOT obstruction or regurgitation, center discretion should be considered in accordance with usual clinical practice.

Potential device-related adverse events that may occur following device implantation include the following: stent fracture, device embolization or migration of the device, perforation of a heart chamber, arrhythmia, allergic reaction to contrast media, cerebrovascular events (TIA, CVA), infection/abscess, fever, hematoma, radiation-induced ectasia, pain, swelling or bruising at the catheterization site.

Potential procedural complications that may result from implantation of the Melody device include the following: rupture of the RVOT conduit, compression of a coronary artery, perforation of a major blood vessel, embolization or migration of the device, perforation of a heart chamber, arrhythmia, allergic reaction to contrast media, cerebrovascular events (TIA, CVA), infection/abscess, fever, hematoma, radiation-induced ectasia, pain, swelling, or bruising at the catheterization site.

Potential device-related adverse events that may occur following device implantation include the following: stent fracture, device embolization or migration of the device, perforation of a heart chamber, arrhythmia, allergic reaction to contrast media, cerebrovascular events (TIA, CVA), infection/abscess, fever, hematoma, radiation-induced ectasia, pain, swelling, or bruising at the catheterization site.

The term “stenfracture” refers to the fracturing of the Melody TPV. However, in subjects with multiple stents in the RVOT it is difficult to definitively attribute stent fractures to the Melody frame versus another stent. For additional information, please refer to the Instructions for Use provided with the product or available on http://manuals.medtronic.com.

CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician.

Important Labeling Information for Geographies Outside of the United States

Indications: The Melody TPV is indicated for use in patients with the following clinical conditions:
- Patients with regurgitant prosthetic right ventricular outflow tract (RVOT) conduits or bioprostheses with clinical indication for invasive or surgical intervention, OR
- Patients with stenotic prosthetic RVOT conduits or bioprostheses where the risk of worsening regurgitation is a relative contraindication to balloon dilatation or stenting.

Contraindications:
- Venous anatomy unable to accommodate a 22 Fr size introducer sheath.
- Implantation of the TPV in the left heart.
- RVOT unfavorable for good stent anchorage.
- Severe RVOT obstruction, which cannot be dilated by balloon
- Obstruction of the central veins.
- Clinical or biological sign of infection
- Active endocarditis.
- Known allergy to aspirin or heparin
- Pregnancy.

Potential Complications/Adverse Events: Potential procedural complications that may result from implantation of the Melody device include the following: rupture of the RVOT conduit, compression of a coronary artery, perforation of a major blood vessel, embolization or migration of the device, perforation of a heart chamber, arrhythmia, allergic reaction to contrast media, cerebrovascular events (TIA, CVA), infection/abscess, fever, hematoma, radiation-induced ectasia, pain, swelling or bruising at the catheterization site.

Potential device-related adverse events that may occur following device implantation include the following: stent fracture, stent fracture resulting in recurrent obstruction, endocarditis, embolization or migration of the device, rupture of a heart chamber, arrhythmias, allergic reaction to contrast media, cerebrovascular events (TIA, CVA), infection/abscess, fever, hematoma, radiation-induced ectasia, pain, swelling, or bruising at the catheterization site.

The term “stenfracture” refers to the fracturing of the Melody TPV. However, in subjects with multiple stents in the RVOT it is difficult to definitively attribute stent fractures to the Melody frame versus another stent.

For additional information, please refer to the Instructions for Use provided with the product or available on http://manuals.medtronic.com.

The Melody Transcatheter Pulmonary Valve and Ensemble II Transcatheter Valve Delivery System has received CE Mark approval and is available for distribution in Europe.
Introduction

Children with severe pulmonary hypertension (PH) who have failed medical therapy have limited treatment options and often die from right heart failure. A surgical procedure known as a Potts shunt is an old technique, originally developed for "blue babies," that is showing promise as an alternative therapy for treating children with severe, drug-resistant PH, possibly delaying or even negating the need for lung transplantation. A Potts shunt is a side-to-side connection from the left pulmonary artery to the descending aorta, resulting ideally in a right-to-left shunt in a child with suprasystemic right heart pressures (Figure 1). The 1940s version was the reverse and was created for children who didn’t have enough pulmonary blood flow. This new twist on the procedure diverts de-oxygenated blood down the descending aorta, reducing pressures within the right ventricle, and hopefully preserving its function.

The first case series published using the Potts shunt in children with severe PH came from the French group in 2012 (Baruteau et al.) Their initial and subsequent experience demonstrated that children with severe disease treated with a Potts shunt showed significant and sustained clinical improvement often with a reduction in onerous medical therapy. They theorized that by reducing right ventricular pressures to systemic levels, they would recapitulate the same physiology seen in Eisenmenger’s Syndrome (ES) and hopefully confer the same superior survival rates seen with Eisenmenger patients, which has been reported as for long as a median of 30-40 years (Kempny et al. Eur Heart Journal, 2017). While such long-term survival remains to be seen, the French group has cohorts of children post-Potts shunt who have sustained their improvement beyond the median survival of similar children undergoing lung transplantation (Baruteau et al 2014; Goldstein et al 2011). In 2013, we began applying this technique at St. Louis Children’s Hospital. We have thus far, the largest experience in North America for this modality of therapy (15 children to date). We recently performed the procedure on a four-month-old male patient, to our knowledge, making him the world’s youngest recipient of a “reverse” Potts shunt.”

We recently performed the procedure on a four-month-old male patient, to our knowledge, making him the world’s youngest recipient of a “reverse” Potts shunt.”
knowledge, making him the world’s youngest recipient of a “reverse” Potts shunt.

The Case

In March 2017, a term infant presented at 19 Days of Life with tachypnea and cyanosis to a local hospital in New York state, where he quickly decompensated, became profoundly hypoxemic, resulting in emergent intubation. The initial echocardiogram demonstrated severe right ventricular hypertension, a patent foramen ovale with right to left shunting, and an otherwise structurally normal heart. Continued struggles with oxygenation led eventually to the child being placed on veno-arterial extracorporeal membrane oxygenation (ECMO). With subsequent aggressive medical therapy, including use of PH specific medications, the child was successfully decannulated from ECMO although he still required substantial ICU care. Despite decannulation, his PH remained severe, with suprasystemic right heart pressures. Pulmonary angiogram demonstrated markedly abnormal pulmonary arteries (diffusely hypoplastic with truncated branching patterns) suggesting that the child’s PH was due to developmental abnormalities of the pulmonary bed. With little improvement in his PH, the child was transferred to our institution for possible Potts shunt or lung transplantation.

The patient came to St. Louis Children’s Hospital on full mechanical ventilation via tracheostomy, FiO₂ 60%, inhaled nitric oxide, epoprostenol, milrinone and sildenafil. Our echocardiogram confirmed the presence of suprasystemic right ventricular pressures with a BNP of 2697 pg/ml (normal <39 pg/ml). After evaluation and discussion, he underwent an uncomplicated Potts shunt with direct anastomosis between the descending aorta and the Left Pulmonary Artery (LPA). His post-operative course was uncomplicated, and he was transferred back home on Post-operative Day 13. At the time of transfer, he was no longer on IV or inhaled vasoactive medications. He was on CPAP pressure support while awake with upper extremity saturations >90% on FiO₂ 40%. BNP was 52 pg/ml. The child was eventually discharged home, and is now a year out from his Potts shunt or lung transplantation.

Discussion

Pulmonary hypertension in children can be a devastating diagnosis with very poor outcomes. Until recently, for children with severe PH who have failed medical therapy, lung transplantation has been the only option. Now, however, treating these children with a Potts shunt has proven to be a successful strategy in palliating their disease and providing an attractive alternative. Success has led to a significant improvement in quality of life and other diagnostic markers of disease, often with a concomitant decrease in medication burden. Sustained benefit has been seen extending beyond 8-10 years post-shunt (Barteau et al 2014). The ages of successfully treated children ranges from the infant to the teenager with a variety of different etiologies for their PH. At our institution, we do not consider a Potts shunt a contraindication to future lung transplant. In fact, we have successfully transplanted a child who failed to improve
from his Potts shunt due to progressive right ventricular failure. While long term benefits remain to be seen, we feel the Potts shunt holds great promise in treating a child with severe PH and should be a part of every pediatric PH caregiver’s armamentarium. To that end, we, along with the French group, have initiated an international Potts shunt registry to help gather worldwide data on how this relatively simple procedure can be utilized for treating these very compromised children.

Conclusion

Potts shunt has the potential to offer children with severe pulmonary hypertension the possibility of extended survival and improved quality of life. The Potts shunt should be considered as the first interventional step in the management of children with severe pulmonary hypertension who are being considered for possible lung transplantation.

References

Figure 1: The Potts Shunt Procedure. New England Journal of Medicine. Video: https://vimeo.com/242605030

About the Authors

Pirooz Eghtesady, MD, PhD
Dr. Eghtesady is Emerson Chair of Pediatric Cardiothoracic Surgery at Washington University School of Medicine in St. Louis, and Cardiothoracic Surgeon-in-Chief at St. Louis Children’s Hospital. He is also Co-Director of the St. Louis Children’s and Washington University Heart Center.

R. Mark Grady, MD
Dr. Grady is a Pediatric Cardiologist at St. Louis Children’s and Washington University Heart Center. He is also an Associate Professor of Pediatrics, Cardiology at Washington University School of Medicine in St. Louis.
Quality and Experience
VSD Occlusion System
Nit-Occlud® Lê VSD

› Patented coil design with polyester fibres
› For perimembranous and muscular VSDs
› Implantable through a 6 F and 7 F sheath
› No device related permanent AV-Block reported

www.pfmmedical.com

Safety for the patient’s benefit

Nit-Occlud® Lê VSD adapts perfectly to the anatomy of perimembranous VSDs (especially in those with aneurysmatic formation) as well as muscular VSDs.

Due to the flexible design of Nit-Occlud® Lê VSD, no permanent AV-Block occurred since its launch in 2010. 350¹,² reported cases with 0% AV-Blocks confirmed this experience.

Scan the QR code or follow the link and see how the implant works

www.pfmmedical.com/clip-vsd

¹ “International Multicentre Clinical Device Investigation on Safety and Effectiveness of the Nit-Occlud® Lê VSD Spiral Coil System for VSD Occlusion” (clinicaltrials.gov identifier NCT00390702).
AI That Sees the Invisible: AliveCor and Mayo Clinic Announce Collaboration to Develop Groundbreaking AI Technology to Help Prevent Sudden Cardiac Death

AliveCor, a leader in FDA-cleared personal electrocardiogram (ECG) technology, today announced a collaboration with Mayo Clinic to develop tools for medical and non-medical personnel to easily screen for Long QT Syndrome (LQTS) early by combining AliveCor’s AI technology with Mayo’s patented algorithms. LQTS is both a congenital and acquired disorder; the inherited form leaves 160,000 people in the U.S. vulnerable to this deadly disease and causes 3,000 to 4,000 sudden deaths in children and young adults annually in the U.S. The acquired form of LQTS is often caused by medications, such as antibiotics and antidepressants, prescribed to many millions of patients every year.

Through this collaboration, new methods and techniques to detect LQTS will be developed for AliveCor’s Kardia Mobile device, a device that is both portable and affordable. The collaboration envisions a tool that will enable people to practice preventive medicine on an unprecedented scale and provide instantaneous results previously unavailable unless patients visited a doctor’s office.

“To prevent this type of sudden death, increased awareness and screening is critical. AliveCor’s patented artificial intelligence technology, algorithms and millions of ECGs, paired with Mayo Clinic’s extensive data and world-leading clinical expertise will mean enhanced safety and decreased risk for many,” said Vic Gundotra, CEO, AliveCor. “This new technology could one day allow pharmacists, coaches and others to actively screen for and prevent sudden cardiac deaths.”

AliveCor provides the first consumer-ready, clinically validated and FDA-cleared ECG to give patients a more complete view of their heart health, improve proactive monitoring and create a new standard of cardiac care. The ECG holds a vast amount of information about a person’s overall health and applies machine learning to millions of ECG recordings as an important enhancement to the traditional ECG analysis.

“This agreement makes our vision of universal screening for the early detection of Long QT Syndrome – a potentially lethal, yet highly treatable condition – one step closer to reality. The electrical heart cycle is emerging as the next vital sign. With very few exceptions, we now know that a prolonged cycle – whether caused by genetics, drugs, electrolyte disturbances or by other diseases – indicates increased risk for early death,” said Michael J. Ackerman, MD, PhD, Director of Mayo Clinic’s Windland Smith Rice Sudden Death Genomics Laboratory. “Any of these deaths could be averted with simple preventive and/or counteractive measures.”

The investment from Mayo adds to the recent infusion of $30 million of capital AliveCor received in spring of 2017 and will accelerate innovations in heart health and continue the rapid expansion of the business.
Mayo Clinic and Dr. Michael J. Ackerman have a financial interest in the technology referenced in this news release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

The FDA-cleared Kardia Mobile is the most clinically validated mobile ECG solution on the market and is recommended by leading cardiologists and used by people worldwide for accurate ECG recordings. Kardia Pro is the first AI-enabled platform for doctors to monitor patients for the early detection of AF. For more information, visit alivecor.com.


For many years, physicians have known that women with diabetes face an increased risk of giving birth to babies with heart defects. Some studies have also suggested a link between non-diabetic mothers’ blood sugar levels and babies’ heart defect risk. However, the new study, led by researchers at the Stanford University School of Medicine, is the first to examine this question in the earliest part of pregnancy, when the fetal heart is forming.

"Most women who have a child with Congenital Heart Disease are not diabetic," said the study’s senior author, James Priest, MD, Assistant Professor of Pediatric Cardiology. "We found that in women who don’t already have diabetes or develop diabetes during pregnancy, we can still measure risk for having a child with Congenital Heart Disease (CHD) by looking at their glucose values during the first trimester of pregnancy."

The study’s lead author is Emmi Helle, MD, PhD, an affiliate in Pediatric Cardiology and former postdoctoral scholar.

One challenge associated with conducting the research was the fact that maternal blood glucose is not routinely measured in non-diabetic pregnant women. Instead, women typically receive an oral glucose tolerance test halfway through pregnancy to determine whether they have gestational diabetes, but this test is performed well after the fetal heart has formed.

The research team studied medical records from 19,107 pairs of mothers and their babies born between 2009 and 2015. The records included details of the mothers’ prenatal care, including blood test results and any cardiac diagnoses made for the babies during pregnancy or after birth. Infants with certain genetic diseases, those born from multiple pregnancies and those whose mothers had extremely low or high body-mass-index measures were not included in the study. Of the infants in the study, 811 were diagnosed with congenital heart disease, and the remaining 18,296 were not.

The scientists analyzed blood glucose levels from any blood sample collected from the mothers between four weeks prior to the estimated date of conception and the end of the 14th gestational week, just after the completion of the first trimester of pregnancy. These early blood glucose measurements were available for 2,292, or 13%, of women in the study. The researchers also looked at the results of oral glucose tolerance tests performed around 20 weeks of gestation, which were available for 9,511, or just under half, of the women in the study.

The research team studied medical records from 19,107 pairs of mothers and their babies born between 2009 and 2015. The records included details of the mothers’ prenatal care, including blood test results and any cardiac diagnoses made for the babies during pregnancy or after birth. Infants with certain genetic diseases, those born from multiple pregnancies and those whose mothers had extremely low or high body-mass-index measures were not included in the study. Of the infants in the study, 811 were diagnosed with congenital heart disease, and the remaining 18,296 were not.

The scientists analyzed blood glucose levels from any blood sample collected from the mothers between four weeks prior to the estimated date of conception and the end of the 14th gestational week, just after the completion of the first trimester of pregnancy. These early blood glucose measurements were available for 2,292, or 13%, of women in the study. The researchers also looked at the results of oral glucose tolerance tests performed around 20 weeks of gestation, which were available for 9,511, or just under half, of the women in the study.

The research team studied medical records from 19,107 pairs of mothers and their babies born between 2009 and 2015. The records included details of the mothers’ prenatal care, including blood test results and any cardiac diagnoses made for the babies during pregnancy or after birth. Infants with certain genetic diseases, those born from multiple pregnancies and those whose mothers had extremely low or high body-mass-index measures were not included in the study. Of the infants in the study, 811 were diagnosed with congenital heart disease, and the remaining 18,296 were not.

The scientists analyzed blood glucose levels from any blood sample collected from the mothers between four weeks prior to the estimated date of conception and the end of the 14th gestational week, just after the completion of the first trimester of pregnancy. These early blood glucose measurements were available for 2,292, or 13%, of women in the study. The researchers also looked at the results of oral glucose tolerance tests performed around 20 weeks of gestation, which were available for 9,511, or just under half, of the women in the study.

The research team studied medical records from 19,107 pairs of mothers and their babies born between 2009 and 2015. The records included details of the mothers’ prenatal care, including blood test results and any cardiac diagnoses made for the babies during pregnancy or after birth. Infants with certain genetic diseases, those born from multiple pregnancies and those whose mothers had extremely low or high body-mass-index measures were not included in the study. Of the infants in the study, 811 were diagnosed with congenital heart disease, and the remaining 18,296 were not.

The scientists analyzed blood glucose levels from any blood sample collected from the mothers between four weeks prior to the estimated date of conception and the end of the 14th gestational week, just after the completion of the first trimester of pregnancy. These early blood glucose measurements were available for 2,292, or 13%, of women in the study. The researchers also looked at the results of oral glucose tolerance tests performed around 20 weeks of gestation, which were available for 9,511, or just under half, of the women in the study.

The research team studied medical records from 19,107 pairs of mothers and their babies born between 2009 and 2015. The records included details of the mothers’ prenatal care, including blood test results and any cardiac diagnoses made for the babies during pregnancy or after birth. Infants with certain genetic diseases, those born from multiple pregnancies and those whose mothers had extremely low or high body-mass-index measures were not included in the study. Of the infants in the study, 811 were diagnosed with congenital heart disease, and the remaining 18,296 were not.

The scientists analyzed blood glucose levels from any blood sample collected from the mothers between four weeks prior to the estimated date of conception and the end of the 14th gestational week, just after the completion of the first trimester of pregnancy. These early blood glucose measurements were available for 2,292, or 13%, of women in the study. The researchers also looked at the results of oral glucose tolerance tests performed around 20 weeks of gestation, which were available for 9,511, or just under half, of the women in the study.

The research team studied medical records from 19,107 pairs of mothers and their babies born between 2009 and 2015. The records included details of the mothers’ prenatal care, including blood test results and any cardiac diagnoses made for the babies during pregnancy or after birth. Infants with certain genetic diseases, those born from multiple pregnancies and those whose mothers had extremely low or high body-mass-index measures were not included in the study. Of the infants in the study, 811 were diagnosed with congenital heart disease, and the remaining 18,296 were not.

The scientists analyzed blood glucose levels from any blood sample collected from the mothers between four weeks prior to the estimated date of conception and the end of the 14th gestational week, just after the completion of the first trimester of pregnancy. These early blood glucose measurements were available for 2,292, or 13%, of women in the study. The researchers also looked at the results of oral glucose tolerance tests performed around 20 weeks of gestation, which were available for 9,511, or just under half, of the women in the study.
WE OFFER...

• Business Development
• Clinical Planning & Research
• Clinical Study Development
• Concept Development
• Coordination of Testing
• Design & Development
• Design Requirements
• Expert Assistance
• FDA Liaison
• Feasibility Evaluation
• Functional & Performance Studies
• Internal Compliance Audits
• Manage All Activities Related to Regulatory Approval & Compliance.
• Market Assessment (Global)
• Pre-Submission Meetings
• Post-Market Surveillance
• Project Management
• Risk Analysis & Management
• Risk-Benefit Analysis
• Report Writing
• Strategic Project Planning
• Supplier Audits

ARE YOU:

• Leading an early stage privately held healthcare organization?
• A large multinational organization?

If you answered “Yes,” then you need a partner who understands your needs, and can effectively navigate and manage the challenges and risks associated with leading the priorities of managing your device through regulatory requirements, clinical trial conduction, downstream and upstream marketing activities to get your product launched on the market within your timeline and representing your vision.

Amber Kingston
2305 Woodmont Circle
Ste. K
Macungie, PA 18062
Tel: 610.463.4964

akkingston@icloud.com
When Risk Is Elevated

After excluding women who had diabetes before pregnancy or who developed it during pregnancy, the results showed that the risk of giving birth to a child with a Congenital Heart Defect was elevated by 8% for every increase of 10 milligrams per deciliter in blood glucose levels in the early stages of pregnancy.

The next step in the research is to conduct a prospective study that follows a large group of women through pregnancy to see if the results are confirmed, Priest said. If researchers see the same relationship, it may be helpful to measure blood glucose early in pregnancy in all pregnant women to help determine which individuals are at greater risk for having a baby with a heart defect, he said.

"We could use blood glucose information to select women for whom a screening of the fetal heart could be helpful," Priest said, adding that modern prenatal imaging allows for detailed diagnoses of many congenital heart defects before birth. "Knowing about defects prenatally improves outcomes because mothers can receive specialized care that increases their babies' chances of being healthier after birth."

The work is an example of Stanford Medicine's focus on precision health, the goal of which is to anticipate and prevent disease in the healthy and precisely diagnose and treat disease in the ill.

Call for Europe-Wide Screening of Babies for Heart Defects

Newswire. All babies across Europe should be routinely screened for Critical Congenital Heart Defects (CCHD) within 24 hours of their birth, say a group of experts led by a University of Birmingham Professor and Honorary Consultant Neonatologist at Birmingham Women's Hospital.

The European Pulse Oximetry Screening Workgroup (EPOSW), a group of neonatologists and paediatric cardiologists, including presidents of leading European Neonatal Scientific Societies, has published a consensus statement recommending screening with pulse oximetry for all babies across Europe.

CCHD occur in around two in every 1,000 newborn babies, and are a leading cause of infant death. Timely diagnosis is crucial for the best outcome for these babies, but current screening methods may miss up to 50% of affected newborn infants, and those sent home before diagnosis frequently die or suffer major morbidity. However, babies with CCHD often have low blood oxygen levels which can be detected quickly and non-invasively by pulse oximetry screening (POS), using a simple sensor placed on newborn infants' hand and foot.

This medical device monitors the oxygen saturation of a patient's blood through their skin, as opposed to measuring oxygen levels directly through a blood sample.

EPOSW's statement, published in Lancet Child Adolescent Health, is a culmination of almost a decade's work and calls for POS in all European countries for newborn babies after six hours of life or before discharge - preferably within 24 hours of birth.

The recommendations follow the PulseOx study led by a team from University of Birmingham and Birmingham Women's Hospital in 2011,
which screened over 20,000 newborn babies for critical heart defects using POS. This study, and an important meta-analysis of the test published by the same team in 2012, has led to POS being used by an increasing number of hospitals in the UK and Europe. However, to date, only a few countries such as Poland, Ireland and Switzerland have issued national guidelines recommending universal screening with pulse oximetry.

Senior author Professor Andrew Ewer, of the Institute of Metabolism and Systems Research at the University of Birmingham, said, “These recommendations are the culmination of almost a decade’s work driven by one focus; to prevent as many babies as possible from dying as a result of undetected heart defects. "Surgical and catheter interventions for CCHD now lead to excellent outcomes for most cases of CCHD, but timely detection is essential. POS improves early detection of CCHD in newborn babies by identifying those with low oxygen saturations. "POS has been shown to be simple, quick, painless, consistent and cost-effective and acceptable to both staff and parents. We have tried to create common, shared, flexible, and evidence-based recommendations for use and standardisation of POS for early detection of CCHD across Europe. These recommendations should be considered at a national level as an approach to better identify CCHD, and other life-threatening conditions, in newborn babies.”

The UK National Screening Committee is currently considering the evidence for POS and whether it should be introduced to the UK national screening programme.

The European Pulse Oximetry Screening Workgroup comprises of Paolo Manzoni, Gerard R Martin, Luc Ji Zimmermann, Anne de-Wahl Granelli, Avroy A Fanaroff, Ilona C. Narayen, Daniele De Luca, Julie Thomas-de-Wahl Granelli, Avroy A Fanaroff, Ilona C.

A pulse oximeter is a machine which can measure, non-invasively, the amount of oxygen being carried around the body by the red blood cells called oxygen saturations. Oxygen from the lungs is bound to hemoglobin in the red-blood cells forming oxyhemoglobin. If oxygen is not bound then this forms de-oxyhemoglobin. In health, almost all haemoglobin is oxyhemoglobin and so the oxygen saturations (i.e. the percentage of haemoglobin which has bound oxygen) is close to 100%. The pulse oximeter measures this by passing light through the peripheral blood vessels (e.g. a finger-tip in an adult or a hand or foot in a baby). Oxyhaemoglobin and de-oxyhaemoglobin absorb this light in different way and the proportion of light absorbed can be analysed by software within the oximeter which then calculates the percentage of haemoglobin saturated with oxygen.

To read the PulseOx Study led by the University of Birmingham in 2011 visit: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)60753-8/abstract and for the meta-analysis visit http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60107-X/fulltext

Birmingham Women's Hospital,part of Birmingham Women's and Children's NHS Foundation Trust, is a centre of excellence, providing a range of specialist health care services to over 50,000 women and their families every year from Birmingham, the West Midlands and beyond. As well as delivering over 8,000 babies a year, it offers a full range of gynaecological, maternity and neonatal care, as well as a comprehensive genetics service, which serves men and women. Its fertility centre is one of the best in the country, while the fetal medicine centre receives regional and national referrals. The hospital is also an international centre for education, research and development with a research budget of over £3 million per year. In April 2016, it was announced as the national miscarriage research centre - the first of its kind in the UK - in partnership with Tommy's Baby Charity.

The Westin Downtown Memphis

Save the Date
May 18-19, 2018
The International PDA Symposium

Le Bonheur Children's Hospital

CONGENITAL CARDIOLOGY TODAY © 2018 by Congenital Cardiology Today (ISSN 1554-7787-print; ISSN 1554-0499-online). Published monthly. All rights reserved.
www.CongenitalCardiologyToday.com

Publication Company Address:
11502 Elk Horn Dr. Ste. 201 
Clarksburg, MD 20871 USA
Tel: +1.301.279.2005

Publishing Management:
• Tony Carlson, Founder, President & Sr. Editor - TCarlsonmd@gmail.com
• Richard Koulbanis, Group Publisher & Editor-in-Chief - RichardK@CCT.bz
• John W. Moore, MD, MPH, Group Medical Editor - JMoore@RCHSD.org
• Kate Baldwin, Sr. Editor - Special Projects - Kate.baldwin@gmail.com

Editorial Board: Teiji Akagi, MD; Zohair Al Halees, MD; Mazeni Alwi, MD; Felix Berger, MD; Fadi Bitar, MD; Jacek Bialkowski, MD; Mario Carminati, MD; Anthony C. Chang, MD, MBA; John P. Cheatham, MD; Bharat Dalvi, MD, MBBS, DM; Horacio Faella, MD; Yun-Ching Fu, MD; Felipe Heusser, MD; Ziyad M. Hijazi, MD, MPH; Ralf Holzer, MD; Marshall Jacobs, MD; R. Krishna Kumar, MD, DM, MBBS; John Lambert, MD; Gerald Ross Marx, MD; Tarek S. Momenah, MBBS, DCH; Toshiro Nakashishi, MD, PhD; Carlos A. C. Pedra, MD; Daniel Penny, MD, PhD; James C. Perry, MD; P. Syamasundar Rao, MD; Shakeel A. Qureshi, MD; Andrew Redington, MD; Carlos E. Ruiz, MD, PhD; Girish S. Shirali, MD; Horst Sievert, MD; Hidemi Tomita, MD; Gil Wernovsky, MD; Zhuoming Xu, MD, PhD; William C. L. Yip, MD; Carlos Zabal, MD

Free Subscription to Qualified Professionals: Send your name, title(s), hospital or practice name, work address and url, phone, fax and email to: sub@cct.bz

Statements or opinions expressed in Congenital Cardiology Today reflect the views of the authors and sponsors, and are not necessarily the views of Congenital Cardiology Today.

Official publication of the CHiP Network
The NuDEL™ Stent Delivery System is designed for the efficient and effective treatment of Coarctation of the Aorta.

The NuDEL includes a triaxial balloon in balloon designed catheter with a Covered Mounted CP Stent™, which is then covered by a sheath as an all-in-one system. Combining the proven technologies of our NuMED BIB® balloon catheter and our Covered CP Stent™, the NuDEL System employs both our compact delivery method and the “zig” pattern stent design.

The NuDEL System is available for immediate purchase in the EU. Contact us or your local distributor to place an order.